Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis

Abstract

Doxazosin, if administered early, may be useful for preventing the prostate tumor formation, and also for limiting or completely suppressing the metastasis of prostate cancer in the TRAMP model. The mechanism of doxazosin is consistent with the established hypothesis.

Possible Anticancer Activity of Rosuvastatine, Doxazosin, Repaglinide and Oxcarbazepin

“…Several signaling pathways have been identified to explain doxazosin-induced anoikis and cell apoptosis, namely through activation of transforming growth factor-b and InB pathways (Partin et al, 2003). inhibition of protein kinase B/Akt activation (Shaw et al, 2004); induction of death receptor-mediated apoptosis (Garrison and Kyprianou, 2006); increase in Bax expression (Chiang et al, 2005) and reduction in focal adhesion kinase (Walden et al, 2004). Doxazosin increased the apoptotic rate and total cell death rate of the HeLa cells in a dose-dependent manner and upregulated the expression of AP-2alpha and caspase-3 (Gan et al, 2008).…”

Significance of Expression of Human METCAM/MUC18 in Nasopharyngeal Carcinomas and Metastatic Lesions

“…The extract from each frozen normal NP or NPC tissue was prepared as described (Wu et al, 2001a;Wu et al, 2001b;Wu, 2004;Wu et al, 2005;Chiang et al, 2005;Wu et al, 2008;Wu et al, 2011;Zeng et al, 2011;Zeng et al, 2012a). A portion of the homogenate was used for RNA preparation as described above.…”

“…A portion of the homogenate was used for RNA preparation as described above. The rest of the homogenate was used for making a Western blot lysate (Wu et al, 2001a;Wu et al, 2001b;Wu, 2004;Wu et al, 2005;Chiang et al, 2005;Wu et al, 2008;Wu et al, 2011;Zeng et al, 2011;Zeng et al, 2012a). HuMETCAM/MUC18 protein expression in cellular and tissue extracts was determined by the standard procedure of Western blot analysis by using a 1/235-350 dilution of the chicken anti-recombinant huMETCAM/ MUC18 protein IgY (reacting at room temperature for 2-5 hours or at the cold room for 16 hours) (Wu et al, 2001a;Wu et al, 2001b;Wu, 2004;Wu et al, 2005;Wu et al, 2008;Wu et al, 2011;Zeng et al, 2011;Zeng et al, 2012a).…”

“…A human malignant melanoma tissue section was used as an external positive control for the immunohistochemistry. The human tissue sections of a few melanoma cases, 7 specimens from normal patients, and 94 specimens from NPC patients were de-paraffinized, and rehydrated, and immunohistochemically stained as described (Wu et al, 2001a;Wu et al, 2001b;Wu, 2004;Wu et al, 2005;Chiang et al, 2005;Wu et al, 2008;Wu et al, 2011;Zeng et al, 2011;Zeng et al, 2012a). The primary antibody used was the chicken anti-recombinant huMETCAM/ MUC18 protein IgY (1/500 dilution) and the secondary antibody the biotinylated rabbit anti-chicken IgY (1/250 dilution) (G289A, Promega) (Wu et al, 2001a;Wu et al, 2001b;Wu, 2004 Wu et al, 2008;Wu et al, 2011;Zeng et al, 2011;Zeng et al, 2012a).…”

A Review of Phase III Clinical Trials of Prostate Cancer Chemoprevention

“…27 This model develops prostate carcinoma that mimics the heterogeneity of human disease and metastasises to lymph nodes, lung and occasionally bone or kidney. 28 To date, the TRAMP model has been used to show that: (i) celecoxib delays prostate carcinogenesis, reduces primary tumour size and prevents metastasis; 29,30 (ii) green tea polyphenols 31 and doxazocin 32 reduce primary tumour growth and inhibit metastasis completely; and (iii) genistein from soy reduces the incidence of poorly differentiated carcinoma. 33 The development of biomarkers will be a necessary step in the effective screening of all the potential agents in smaller phase II trials.…”